Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva.
The lawsuit claims that Samsung Bioepis’ biosimilar products infringe up to 34 patents covering Amgen’s blockbuster drugs. The claim also includes a request to block Samsung Bioepis from continuing to make and sell their drug products, with an unspecified amount of monetary damage. Amgen claims that Samsung Bioepis’ biosimilars infringe patents covering the API denosumab found in Prolia and Xgeva, as well as technology related to the drugs.
Biosimilars are biologic drug products akin to generics for traditional pharmaceuticals. They are complex products made from living cells or tissues, and cannot be copied exactly. In a statement to the court, Amgen stated that Samsung had applied for US FDA permission to market biosimilars of Prolia and Xgeva. Prolia is used in patients with osteoporosis and those at high risk for broken bones, while Xgeva aids in preventing fractures in patients with bone cancer. Over US$2.7 billion worth of Prolia was sold in the US last year, while Xgeva saw sales of up to US$1.5 billion. A similar dispute was brought forth between Amgen and Sandoz after the FDA granted approval to biosimilars developed and marketed by Sandoz.
Both Amgen and Samsung declined to comment on the lawsuit.
Source:
Amgen sues Samsung biotech unit over bone drug copies [Accessed August 14, 2024] https://www.reuters.com/legal/litigation/amgen-sues-samsung-biotech-unit-over-bone-drug-copies-2024-08-13/
Related News
-
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Alzheimer’s drug Leqembi rejected by EU drug regulator
The European Medicine’s Agency (EMA), the drug regulator for the EU, rejected Eisai and Biogen’s Alzheimer’s drug product Leqembi, citing the drug’s slowing of cognitive decline did not outweigh the risk of serious brain swellin... -
News Second obesity drug candidate from Roche shows early trial success
Following from its purchase of Carmot Therapeutics, Roche have announced positive early-stage trial success for its second obesity drug candidate acquired from Carmot Therapeutics. -
News Tumour microproteins could provide basis for cancer vaccines
A recent study published in Science Advances has identified a set of microproteins produced exclusively in liver tumours, which may provide a clear target for the development of a cancer vaccine.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance